Key Segmentation
By Treatment
-
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
-
Biologic Therapies
-
JAK Inhibitors
-
Disease-modifying Anti-rheumatic Drugs (DMARDs)
-
Corticosteroids
By Route of Administration
-
Parenteral
-
Oral
By Type
-
Prescription Drugs
-
OTC Drugs
By Application
-
Adults
-
Juveniles
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies
Regional Coverage:
North America
-
United States
-
Canada
Europe
-
Germany
-
United Kingdom
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
North America dominated the Ankylosing Spondylitis Market in 2025 with over 56% market share, while Asia Pacific is the fastest-growing region.
NSAIDs dominated with a 48.10% revenue share in 2025, while Biologic Therapies is the fastest growing segment.
The Ankylosing Spondylitis Market is expected to grow at a CAGR of 7.59% from 2026 to 2035.
Growing adoption of biologic therapies, paired with earlier diagnosis driven by better imaging and rising disease awareness among physicians.
The Ankylosing Spondylitis Market was valued at USD 6.68 Billion in 2025.